Business Segments · Goodwill (Note 3)
Innovative Medicine — Goodwill (Note 3)
Johnson & Johnson Innovative Medicine — Goodwill (Note 3) decreased by 1.0% to $14.81B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 35.8%, from $10.91B to $14.81B. Over 4 years (FY 2021 to FY 2025), Innovative Medicine — Goodwill (Note 3) shows an upward trend with a 6.2% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2009
Last reportedQ1 2026Apr 22, 2026
Rolls up toGoodwill
How to read this metric
An increase suggests recent acquisitions, while a decrease may indicate impairment charges or divestitures.
Detailed definition
Represents the total carrying value of goodwill attributed to the Innovative Medicine operating segment as reported in f...
Peer comparison
Commonly reported by large pharmaceutical companies as 'Goodwill' under segment assets.
Metric ID:
jnj_segment_innovative_medicine_goodwill_note_3Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.81B | $10.73B | $10.58B | $10.41B | $10.04B | $9.66B | $10.18B | $10.31B | $10.32B | $10.15B | $10.41B | $10.55B | $10.77B | $11.11B | $10.69B | $10.91B | $14.33B | $14.27B | $14.97B | $14.81B |
| QoQ Change | — | -0.7% | -1.4% | -1.6% | -3.6% | -3.7% | +5.4% | +1.2% | +0.1% | -1.7% | +2.5% | +1.4% | +2.0% | +3.2% | -3.8% | +2.0% | +31.3% | -0.4% | +4.9% | -1.0% |
| YoY Change | — | — | — | — | -7.1% | -9.9% | -3.7% | -1.0% | +2.9% | +5.1% | +2.2% | +2.4% | +4.3% | +9.5% | +2.7% | +3.4% | +33.0% | +28.4% | +40.0% | +35.8% |
Range$9.66B – $14.97B
CAGR+6.9%
Avg YoY Growth+9.2%
Median YoY Growth+3.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — goodwill (note 3)?
- Johnson & Johnson (JNJ) reported innovative medicine — goodwill (note 3) of $14.81B in Q1 2026.
- How has Johnson & Johnson's innovative medicine — goodwill (note 3) changed year-over-year?
- Johnson & Johnson's innovative medicine — goodwill (note 3) increased by 35.8% year-over-year, from $10.91B to $14.81B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — goodwill (note 3)?
- Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — goodwill (note 3) has grown at a 6.2% compound annual growth rate (CAGR), from $42.86B to $54.47B.
- What does innovative medicine — goodwill (note 3) mean?
- The total value of goodwill recorded for the Innovative Medicine business segment.